Center for Translational Viral Oncology (CTVO)

转化病毒肿瘤学中心 (CTVO)

• 批准号: 9209603
• 负责人: Krzysztof Reiss
• 金额: $ 205.01万
• 依托单位: LSU HEALTH SCIENCES CENTER
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-15 至 2022-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9209603
• 关键词: Academic Medical Centers; Academic support; Address; Advisory Committees; Affect; African American; Area; Basic Science; Biological; Biomedical Research; Cell Cycle Regulation; Cell physiology; Cells; Centers of Research Excellence; Cervical; Clinic; Clinical; Clinical Data; Clinical Research; Clinical Trials; Collaborations; Core Facility; Country; Cytomegalovirus; Data; Death Rate; Development; Diagnostic; Disease; Endogenous Retroviruses; Ensure; Extramural Activities; Funding; Future; Gene Expression Regulation; Genome; Goals; HIV; HIV Infections; Head and Neck Cancer; Health; Health Sciences; Healthcare; Hepatitis B; Hepatitis C; Homeostasis; Human; Human Herpesvirus 4; Human Herpesvirus 8; Human Papillomavirus; Immune; Immune response; Incidence; Institution; Interdisciplinary Study; International; JC Virus; Joints; Kaposi Sarcoma; Knowledge; Laboratories; Laboratory Research; Leadership; Louisiana; Lymphoma; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of liver; Mentors; Mentorship; Minority; Molecular; Morbidity - disease rate; Not Hispanic or Latino; Oncogenic; Oncogenic Viruses; Pathogenesis; Patients; Population; Program Development; Public Health; Research; Research Infrastructure; Research Personnel; Research Project Grants; Research Support; Resources; Role; Sampling; Scholarship; Scientist; Signal Transduction; System; Teacher Professional Development; Training; Training Support; Translating; Translational Research; United States National Institutes of Health; Universities; Viral; Virus; Virus Diseases; Vulnerable Populations; Work; base; biobank; carcinogenesis; career; clinical care; clinical infrastructure; clinical material; clinical translation; co-infection; design; epigenetic regulation; experience; health disparity; high risk; interest; leadership development; metropolitan; mortality; neurotropic; novel; novel diagnostics; novel therapeutic intervention; oncology; patient population; prevent; primary effusion lymphoma; programs; treatment strategy; tumor; virus host interaction; virus related cancer

Abstract: The primary goal of this COBRE is to strengthen the biomedical research infrastructure in Louisiana by training Promising Junior Investigators (PJIs) who can develop independent research addressing a major health problem in our region. Virus-associated cancers remain a major cause of morbidity and mortality in our region and disproportionately affect the African American population. These include HPV- associated cervical, anogenital, and head and neck cancers, KSHV-associated Kaposi sarcoma and primary effusion lymphoma, HCV- and HBV-associated liver cancers and others, all which are unusually highly prevalent in our area. Increases in these diseases may be explained, in part, by the large number of HIV-infected patients in the region. In addition, our data also indicate that co-infection of cells with more than one virus promotes or associates with malignant transformation. Therefore, understanding how particular viruses and viral co- infections promote the development of malignancies is essential to identifying and implementing new preventative, diagnostic and treatment strategies. It follows that training a new cadre of investigators capable of conducting novel research in the field of viral oncology is essential for our state. This will be accomplished by developing a Center for Translational Viral Oncology (CTVO) that leverages existing resources in order to train new investigators, develops novel laboratory infrastructure, and supports research projects designed to study these diseases in our unique populations. The CTVO will support the scientific, mentoring and administrative needs of the PJIs by providing (i) experienced mentoring teams composed of NIH-funded and internationally recognized investigators who are committed to guiding PJIs in developing cutting edge research, ensuring their successful training, and supporting their development as independent researchers; (ii) unique clinical material from high risk patient populations – PJIs will have preferential access to a unique (and increasing) set of clinically annotated biospecimens from HIV+ and HIV- patients with virus-associated cancers collected at the University Medical Center – New Orleans (iii) well-established administrative and cutting edge scientific infrastructure including integrated cancer and HIV clinical trials programs to translate the findings of these projects, advanced core research laboratories, and a new expanded and unique biorepository, the HIV/Clinical Tumor Biorepository (HCTB) Core. Initially, this COBRE brings four projects led by PJIs to study the role of oncogenic viruses such as HPV, KSHV and EBV, as well as, viruses of increasing interest in human carcinogenesis such as human cytomegalovirus (HCMV), human endogenous retrovirus sequences (HERVs), and human neurotropic Polyomavirus JC (JCV). These cancers arise more commonly in the setting of immune deficiencies (including HIV infection), and disproportionately affect African American patients in Louisiana. Implementation of the proposed work will be directed by the following Specific Aims: 1) to establish interdisciplinary teams of investigators and laboratory core infrastructure to support PJI-led research projects on virus-host interactions and their role in pathogenesis of cancer; 2) to develop an administrative infrastructure to mentor and promote the independent career of the PJIs; and 3) to leverage institutional NIH-funded Centers and Programs at the participating institutions to facilitate the integration of PJIs within the clinical and translational research infrastructure. The completion of this program will provide this region with enhanced capabilities to address these and other virus related health problems that may arise in the future.

摘要：COBRE 的主要目标是加强路易斯安那州的生物医学研究基础设施 通过培训有前途的初级研究员（PJI），他们可以针对某个专业进行独立研究 与病毒相关的癌症仍然是我们地区发病和死亡的主要原因。 其中包括与 HPV 相关的宫颈癌、 肛门生殖器癌、头颈癌、KSHV 相关的卡波西肉瘤和原发性渗出性淋巴瘤， HCV 和 HBV 相关肝癌及其他癌症在我们地区异常普遍。 这些疾病增加的部分原因可能是该国存在大量艾滋病毒感染者。 此外，我们的数据还表明，细胞同时感染一种以上的病毒会促进或促进病毒的传播。 因此，了解特定病毒和病毒如何共存。 感染促进恶性肿瘤的发展对于识别和实施新的治疗方法至关重要 因此，需要培训一支新的有能力的调查人员队伍。 在病毒肿瘤学领域开展新颖的研究对于我们州来说至关重要。 通过建立一个利用现有资源的转化病毒肿瘤学中心（CTVO） 培训新的研究人员，开发新颖的实验室基础设施，并支持旨在 CTVO 将支持科学、指导和研究，以研究我们独特人群中的这些疾病。 通过提供 (i) 由 NIH 资助和组成的经验丰富的指导团队来满足 PJI 的管理需求 国际公认的研究人员致力于指导 PJI 开发尖端技术 研究，确保他们的成功培训，并支持他们作为独立研究人员的发展； (ii) 来自高风险患者群体的独特临床材料 – PJI 将优先获得独特的临床材料 （并且还在增加）一组来自 HIV+ 和 HIV- 病毒相关患者的临床注释生物样本 在新奥尔良大学医学中心收集的癌症 (iii) 完善的管理和 尖端科学基础设施，包括综合癌症和艾滋病毒临床试验项目，以转化 这些项目的成果、先进的核心研究实验室以及新的扩展和独特的 生物存储库，HIV/临床肿瘤生物存储库 (HCTB) 核心 最初，该 COBRE 带来了四个项目。 PJI 研究 HPV、KSHV 和 EBV 等致癌病毒以及不断增加的病毒的作用 对人类致癌作用的兴趣，例如人巨细胞病毒（HCMV）、人内源性逆转录病毒 序列（HERV）和人类嗜神经性多瘤病毒 JC（JCV）这些癌症更常见于。 免疫缺陷（包括艾滋病毒感染）的情况，并对非裔美国人造成不成比例的影响 路易斯安那州的患者。拟议工作的实施将遵循以下具体目标：1) 建立由研究人员和实验室核心基础设施组成的跨学科团队，以支持 PJI 领导的 关于病毒-宿主相互作用及其在癌症发病机制中的作用的研究项目；2) 开发一种 指导和促进 PJI 独立职业的行政基础设施；以及 3) 发挥杠杆作用； NIH 资助的机构中心和参与机构的项目，以促进整合 该计划的完成将提供临床和转化研究基础设施内的 PJI。 该地区解决这些问题和其他可能出现的与病毒相关的健康问题的能力得到增强 将来。